Movatterモバイル変換


[0]ホーム

URL:


CN1470239A - Testosterone intradermic sustained preparation - Google Patents

Testosterone intradermic sustained preparation
Download PDF

Info

Publication number
CN1470239A
CN1470239ACNA021266832ACN02126683ACN1470239ACN 1470239 ACN1470239 ACN 1470239ACN A021266832 ACNA021266832 ACN A021266832ACN 02126683 ACN02126683 ACN 02126683ACN 1470239 ACN1470239 ACN 1470239A
Authority
CN
China
Prior art keywords
testosterone
teststerone
skin
preparation
scrotum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA021266832A
Other languages
Chinese (zh)
Inventor
王怀秀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to CNA021266832ApriorityCriticalpatent/CN1470239A/en
Publication of CN1470239ApublicationCriticalpatent/CN1470239A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

The invention is a percutaneous absorptive preparation of teststerone. Spread teststerone percutaneous absorption preparation on the skin of scrotum or other parts, the teststerone can permeate the skin to slowly and continuously enter blood circulation, which not only effectively increases teststerone blood concentration, but also keeps teststerone blood concentration stable, so as to achieve the androgen substitution cure for the male sufferer whose gonad function is low.

Description

Testosterone intradermic sustained preparation
The present invention is the percutaneous delayed testosterone-releasing preparation that is used for male gonad hypofunction patient.
Male gonad hypofunction patient PA level is low, shows as the manlike obstacle of sexual dysfunction and secondary sex characteristics.Its Therapeutic Method is an androgen replacement.Treated with oral testosterone, but medicine after being absorbed, digestive tract is at first gone into liver through portal vein wherein most of i.e. inefficacy before the performance drug effect because first pass effect is decomposed in the past.17 α-alkanisation androgen such as methyl testosterone can delay catabolism, but prolonged application can cause cholestasis hepatitis even hepatocarcinoma, so should not be used for the long-term replacement therapy of male gonad hypofunction patient.Though the injection testosterone can be avoided first pass effect, the medicine blood concentration raises immediately significantly after injection, descends rapidly again thereafter, does not meet physiological requirement.It is relatively stable that testosterone subdermal implantation method can be kept the plasma testosterone level, and a heeling-in can be kept 4-6 month, performs the operation but cost an arm and a leg and need, and is difficult for being accepted by the patient.
The transdermal formulation that the objective of the invention is to contain testosterone be coated in scrotum or the skin at other position of being easy to absorb on, the testosterone intradermic skin is slowly absorbed constantly, keep more stable PA concentration, reach hormone replacement therapy effect male gonad hypofunction patient.
Above-mentioned purpose realizes by following measure.The method of preparation testosterone intradermic absorbable preparation is exemplified below:
Prescription: stearic acid 110g, propylene glycol 100g, 10% ammonia solution 30ml, 10% hibitane alcohol liquid 5ml, ethanol 30ml, testosterone 10g, adding distil water make total amount become 1000g.
Compound method: (1) is dissolved in the 10g testosterone in 30ml ethanol and the 70g propylene glycol; (2) the 700ml distilled water is heated to 85-90 ℃, adds stearic acid 110g, constantly be stirred to molten entirely; (3) keep 85 ℃ of temperature, stir adding 10% ammonia solution down, stirred 2-3 minute; (4) add testosterone solution and 5ml10% hibitane alcohol liquid, stirred 15 minutes; (5) with above-mentioned product chilling, room temperature was placed 10-12 hour then, will remain 30g propylene glycol and distilled water mixed liquor again and add, and made total amount become 1000g, stirred evenly.
After preparation finishes, the testosterone intradermic absorbable preparation is packed.During use, regularly evenly be coated on a certain amount of transdermal formulation on the skin at patient's scrotum or other position every day, massages, and disappears until transdermal formulation.
Theoretical basis and advantage that testosterone intradermic absorbs are as follows: the molecular weight of (1) testosterone is less than 300, and is fat-soluble, is easy to enter blood circulation by skin, can effectively improve the haemoconcentration of testosterone, the first pass effect when having avoided oral testosterone simultaneously.(2) slow releasing function had been played in the slowly release of the blood capillary in dermal tissue after the epidermis of skin absorbed the drug, and can make the haemoconcentration of testosterone keep stable.(3) because applied testosterone is a normal hormone in the body, so human body is had no side effect.
At human body, the efficient difference of the skin absorbs medicine of different parts.Through scrotum applications of testosterone transdermal formulation following advantage is arranged: the principal element that (1) influences drug absorption is the cuticle thickness and the shallow degree of blood capillary distribution table of epidermis.The skin of scrotum horny layer as thin as a wafer, blood capillary distributes and almost to reach epidermal area and abundanter.According to surveying and determination, to some drugs, the infiltration rate of scrotum is 10 times of skin of abdomen, is 100 times of vola skin; (2) androgenic physiological action mainly is to realize by the dihydrotestosterone that testosterone generates after 5 α-reduction.Because of containing abundant 5 in the skin of scrotum, a part of testosterone promptly is converted into dihydrotestosterone in absorption process, and blood plasma dihydrotestosterone concentration is obviously improved, the performance higher physiological activities; (3) when scrotum absorbs testosterone, the therapeutic dose testosterone is no more than normal range through the estrogen that aromatization produces.

Claims (1)

CNA021266832A2002-07-282002-07-28Testosterone intradermic sustained preparationPendingCN1470239A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CNA021266832ACN1470239A (en)2002-07-282002-07-28Testosterone intradermic sustained preparation

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CNA021266832ACN1470239A (en)2002-07-282002-07-28Testosterone intradermic sustained preparation

Publications (1)

Publication NumberPublication Date
CN1470239Atrue CN1470239A (en)2004-01-28

Family

ID=34143357

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CNA021266832APendingCN1470239A (en)2002-07-282002-07-28Testosterone intradermic sustained preparation

Country Status (1)

CountryLink
CN (1)CN1470239A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101480399B (en)*2008-09-252011-10-05宋博Application of andrusol in preparing medicament for treating asthenospermia
US8466136B2 (en)2005-10-122013-06-18Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US9125816B2 (en)2000-08-302015-09-08Besins Healthcare Inc.Pharmaceutical composition and method for treating hypogonadism

Cited By (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9125816B2 (en)2000-08-302015-09-08Besins Healthcare Inc.Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en)2000-08-302015-09-15Besins Healthcare Inc.Pharmaceutical composition and method for treating hypogonadism
US8466136B2 (en)2005-10-122013-06-18Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8466138B2 (en)2005-10-122013-06-18Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8466137B2 (en)2005-10-122013-06-18Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8486925B2 (en)2005-10-122013-07-16Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8729057B2 (en)2005-10-122014-05-20Unimed Pharmaeuticals, LLCTestosterone gel and method of use
US8741881B2 (en)2005-10-122014-06-03Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8754070B2 (en)2005-10-122014-06-17Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US8759329B2 (en)2005-10-122014-06-24Unimed Pharmaceuticals, LlcTestosterone gel and method of use
CN101480399B (en)*2008-09-252011-10-05宋博Application of andrusol in preparing medicament for treating asthenospermia

Similar Documents

PublicationPublication DateTitle
EP1871433B1 (en)Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US6465006B1 (en)Method for facilitating absorption of pharmaceutically active compounds
US7094228B2 (en)Methods and formulations for photodynamic therapy
RU2233156C2 (en)Composition for topical application of methylfenidate (variants) and method for treatment of attention deficiency disorder and disorder of type attention deficiency/hyperactivity (variants)
US20140369949A1 (en)Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor
US6726673B1 (en)Methods and apparatus for improved administration of testosterone pharmaceuticals
AU2014344740B2 (en)Vasodilator formulation and method of use
TW200418487A (en)Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
JP2007083091A (en)Apparatus for administration of transdermal pharmaceuticals
JP2005501014A (en) Controlled heat-induced rapid delivery of pharmaceuticals from skin depots
Breuninger et al.Subcutaneous infusion anesthesia with diluted mixtures of prilocain and ropivacain
EP2514414A1 (en)Transdermally absorbed preparation of anti-dementia drug
KR20100126830A (en) Percutaneous Absorption Formulation
US20020114827A1 (en)Methods and apparatus for improved administration of analgesics
KR20070085773A (en) Apparatus and Method for Treating Warts
WO2005079317A2 (en)Prostate hypertrophy treatment composition and method
CN1470239A (en)Testosterone intradermic sustained preparation
CN101036660A (en)Estrogen gel medicine and preparation method thereof
CN1126587A (en)Delayed testosterone-releasing system through scrotum
WO2007119467A1 (en)Percutaneous absorption promoting agent and percutaneous absorption preparation using the same
AU2011302690A1 (en)Treatment of fungal infections
CN1277016A (en)Ointment for treating sweety feet and body odor and its preparation
CN106692112A (en)Strychnine patch for treating local soft tissue inflammatory pain
CN118078730A (en) A soluble microneedle patch with amino acid coordination assembly to enhance hydrophobic drug loading and its preparation and application
CN108969546A (en)A kind of preparation method of sundew plastics

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C12Rejection of a patent application after its publication
RJ01Rejection of invention patent application after publication

[8]ページ先頭

©2009-2025 Movatter.jp